Vasodilators in the treatment of pediatric heart failure

Progress in Pediatric Cardiology

Volumn 12, Issue 1, 2000, Pages 81-90

  Balaguru, Duraisamy ^a   Auslender, Marcelo ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute pediatric heart failure; Afterload; Preload; Shunt physiology; Vasodilators

Indexed keywords

AMRINONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXIMONE; GLYCERYL TRINITRATE; HYDRALAZINE; INOTROPIC AGENT; MILRINONE; MINOXIDIL; NEUROHORMONE; NIFEDIPINE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PHENTOLAMINE; PIPERANOMETOZINE; PRAZOSIN; VASODILATOR AGENT; VERAPAMIL;

ADAPTATION; BLOOD PRESSURE; CHRONIC DISEASE; HEADACHE; HEART AFTERLOAD; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART PRELOAD; HEMODYNAMICS; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; MEDICAL PRACTICE; MORBIDITY; MORTALITY; PEDIATRICS; PRIORITY JOURNAL; REVIEW;

EID: 0033652081     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1058-9813(00)00060-6     Document Type: Article

References (95)

1. Pathophysiology of chronic heart failure
2. How should a physician view heart failure? The philosophical and physiological evolution of three conceptual models of the disease
3. Treatment of congestive heart failure by altering loading conditions of the heart
4. The intrinsic physiologic properties of the developing heart
5. Cardiac preload, afterload, and heart failure
6. Use of the indirect axillary pulse tracing for noninvasive determination of ejection time, upstroke time, ad left ventricular wall stress throughout ejection in infants and young children
7. Use of calibrated carotid pulse tracing for calculation of left ventricular pressure and wall stress throughout ejection
8. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity
9. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents
10. Vasodilator therapy in cardiac failure
11. Vasodilator therapy in children: acute and chronic effects in children with left ventricular dysfunction or mitral regurgitation
12. Hemodynamic effects of hydralazine in infants with larger ventricular septal defect
13. Hemodynamic effects of nitroprusside in infants with a large ventricular septal defects
14. Short-term effects of hydralazine in infants with complete atrioventricular canal defects
15. Guidelines for vasodilator therapy of congestive heart failure in infants and children
16. Hemodynamic effects of hydralazine in infants with idiopathic dilated cardiomyopathy and congestive heart failure
17. Afterload reduction treatment for large ventricular septal defects
18. Significance of systemic vascular resistance in determining the hemodynamic effects of hydralazine on large ventricular septal defects
19. Use of hydralazine for intractable cardiac failure in childhood
20. Acute effects of vasodilators on left-to-right shunts in infants and children
21. Nitroglycerin therapy in children with low cardiac index after heart surgery
22. Afterload reduction and cardiac output in infants early after intracardiac surgery
23. Hemodynamic effects of intravenous nitroglycerin in pediatric patients after heart surgery
24. Vasodilators in VSD
25. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery
26. Acute hemodynamic effects of nitroprusside in children with isolated mitral regurgitation
27. Vasodilator therapy in congestive heart failure
28. Chronic afterload reduction in infants and children with primary myocardial disease
29. Short-term hemodynamic effects of captopril in infants with congestive heart failure
30. Captopril in children with dilated cardiomyopathy: acute and long-term effects in prospective study of hemodynamic and hormonal effects
31. Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation
32. Abnormalities of right ventricular function following Mustard's operation for transposition of great arteries
33. Results of Mustard operation for d-transposition of great arteries
34. Right ventricular function 10 years after the Mustard operation. Analysis of size, shape and wall motion
35. A clinical trial of afterload reduction in postoperative Fontan patient
36. Enalapril does not enhance exercise capacity in patients after Fontan procedure
37. Vasodilator and inotropic drugs for chronic heart failure: distinguishing hype from hope
38. Effect of vasodilator therapy on mortality in chronic heart failure. Results of a veteran administration cooperative study
39. Minoxidil in patients with left heart failure: contrasting hemodynamic and clinical effects in controlled trial
40. Calcium channel blockers in congestive heart failure: theoretical considerations and clinical experience
41. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure
42. Long-term oral amrinone for congestive heart failure: lack of efficacy in multicenter controlled trial
43. for the Enoximone Multicenter Trial Group.: Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo
44. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias
45. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure
46. Sympathetic activity in idiopathic dilated cardiomyopathy. Influence of captopril and hydralazine
47. The cardiac structure-function relationship and renin-angiotensin-aldosterone system in hypertension and heart failure
48. Changing mortality in dilated cardiomyopathy. The Heart Muscle Disease Study Group
49. Central and regional hemodynamic effects of intervenous isosorbide dinitrate, nitroglycerin, and nitroprusside in patients with congestive heart failure
50. Prevention and reversal of nitrate tolerance in patients with congestive heart failure
51. Phenomenon of nitrate tolerance
52. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention
53. Association of methemoglobinemia and intervenous nitroglycerin administration
54. Effects of continuous infusion of intravenous nitroglycerin administration
55. Methemoglobin produced by high-dose intravenous nitroglycerin
56. Nitric oxide and related vasodilators
57. Vasodilators
58. Effects of sodium nitroprusside on left ventricular diastolic pressure-volume relations
59. Effects of nitroprusside on transmitral flow velocity patterns in extreme heart failure. A combined hemodynamic and Doppler echocardiographic study of varying loading conditions
60. The effect of vasodilator therapy on systolic and diastolic time intervals in congestive heart failure
61. Effect of sodium nitroprusside on ventilation-perfusion mismatching in heart failure
62. Platelet function studies in heart disease. Enhanced platelet aggregate formation activity in congestive heart failure. Inhibition by sodium nitroprusside
63. Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe heart failure
64. Positive inotropic effects of hydralazine in human subjects. Comparison with prazocin in the setting of congestive heart failure
65. Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure
66. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal investigators of REFLECT study
67. Inotropic drugs and their mechanism of action
68. Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without heart disease
69. Pharmacology of bipyridine phosphodiesterase III inhibitors
70. Age-related amrinone pharmacokinetics in a pediatric population
71. Amrinone pharmacokinetics in neonates and infants
72. Role of contractile proteins and sarcoplasmic reticulum in the response of the heart to catecholamines: an historic review
73. Regulation of myocardial function in normal and diseased heart: modification by inotropic drugs
74. Amrinone in neonates and infants after cardiac surgery
75. Electrophysiologic effects of milrinone in patients with congestive heart failure
76. Selective pulmonary and systemic vasodilator effects of amrinone in children: new therapeutic implications
77. Hemodynamic effects of amrinone and colloid administration in children following cardiac surgery
78. Pulmonary and systemic hemodynamic effects of amrinone in neonates following cardiopulmonary bypass
79. Developmental changes in the cardiac effects of amrinone in the dog
80. Negative inotropic effects of amrinone in the neonatal piglet heart
81. Safety of amrinone for treating congestive heart failure in a premature neonate
82. A comparison of the hemodynamic effects of amrinone and sodium nitroprusside in infants after cardiac surgery
83. Effect of oral milrinone on mortality in severe chronic heart failure
84. Safety and efficacy of epoprostenol in patients with severe congestive heart failure
85. Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure
86. Neurohumoral inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure
87. Effectiveness of endopeptidase inhibition landoxatril in congestive heart failure
88. Enhancement of endothelium-dependent vasodilatation by low-dose nitroglycerin in patients with congestive heart failure
89. Losartan in heart failure. Hemodynamic effects and tolerability
90. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 Bosentan